Questions? +1 (202) 335-3939 Login
Trusted News Since 1995
A service for healthcare industry professionals · Sunday, January 20, 2019 · 474,167,508 Articles · 3+ Million Readers

Global Therapeutic Landscape for Raynauds Disease- Pipeline Review, H1 2018

Raynauds Disease

PUNE, MAHARASHTRA, INDIA, February 19, 2018 / -- Raynauds Disease


Raynauds disease is a common condition that affects the blood supply to certain parts of the body, usually the fingers and toes. Predisposing factors include age, gender, family history and smoking. Symptoms include fingers, toes, ears, or nose to become white, and then turn blue. Treatment includes vasodilator, alpha blockers and calcium channel blockers.

Click here for sample report @

Top Companies mentioned

Allergan Plc

Apricus Biosciences Inc

Covis Pharmaceuticals Inc

Pfizer Inc

Raynauds Disease Industry Major Outlook

Pharmaceutical and Healthcare latest pipeline guide Raynauds Disease - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Raynauds Disease, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Raynauds Disease (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Raynauds Disease and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II and Preclinical stages are 1, 3 and 1 respectively. Similarly, the Universities portfolio in Unknown stages comprises 1 molecules, respectively.

Raynauds Disease - Competitive Analysis

Key players are making innovative developments in Raynauds Disease industry.  The same will help in improving the market performance. Heavy investments are made by major players in the R&D sector


The pipeline guide provides a snapshot of the global therapeutic landscape of Raynauds Disease.

The pipeline guide reviews pipeline therapeutics for Raynauds Disease by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. 

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Raynauds Disease therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Raynauds Disease therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects. 

The pipeline guide reviews latest news related to pipeline therapeutics for Raynauds Disease.


For Detailed Reading Please visit @

About Us

Wise Guy Reports is part of the Wise Guy Consultants Pvt. Ltd. and offers premium progressive statistical surveying, market research reports, analysis & forecast data for industries and governments around the globe. Wise Guy Reports understand how essential statistical surveying information is for your organization or association. Therefore, we have associated with the top publishers and research firms all specialized in specific domains, ensuring you will receive the most reliable and up to date research data available.

Contact Us:


Partner Relations & Marketing Manager

Ph: +1-646-845-9349 (US)

Ph: +44 208 133 9349 (UK)

Norah Trent
WiseGuy Research Consultants Pvt. Ltd.
+1 646 845 9349 / +44 208 133 9349
email us here

Powered by EIN Presswire

EIN Presswire does not exercise editorial control over third-party content provided, uploaded, published, or distributed by users of EIN Presswire. We are a distributor, not a publisher, of 3rd party content. Such content may contain the views, opinions, statements, offers, and other material of the respective users, suppliers, participants, or authors.

Submit your press release